SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $56

Morgan Stanley maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $58 to $56.

05/10/2021 09:18
Morgan Stanley maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $58 to $56.